Ingrid Delaet (Chief Regulatory Officer) sold 14,571 shares over 3 days for $2,603,112.00 under pre-arranged 10b5-1 plan; retains 16,225 shares plus 42,037 in options
Ingrid Delaet, Chief Regulatory Officer at Neurocrine Biosciences (NBIX), executed three scheduled sales totaling 14,571 shares for $2,603,112.00 at a blended average price of $178.65. This reduction represents a 47.3% decrease from her pre-transaction holdings of 30,796 shares, conducted under a 10b5-1 trading plan adopted on 2026-02-27, meaning the sale was pre-arranged rather than discretionary. Her post-transaction holdings of 16,225 non-derivative shares, coupled with 42,037 remaining shares in non-qualified stock options across three tranches, indicate her overall position in the company remains substantial. The stock has appreciated 9.3% over the prior 30 days and 40.1% over 90 days, trading near its 52-week high of $181.00 at a current price of $180.55, while the company's fundamentals show strong recent performance with $814.5M in latest quarterly revenue, $197.9M net income, and 21.4% annual revenue growth. The structured, calendar-based nature of this transaction removes timing inference and positions it as standard equity plan execution rather than a discretionary signal.